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Hospital Hampstead NHS Trust, London, UK; 3The Royal Free Sheila Sherlock Liver Centre and University Department of Surgery UCL, London, UKPatients with cirrhosis can have abnormalities in laboratory pro-coagulant and anti-coagulant factors, low-grade coagulation
tests reﬂecting changes in primary haemostasis, including bleed-
ing time, platelet function tests, markers of platelet activation,
and platelet count. Such changes have been considered particu-
larly relevant in the bleeding complications that occur in cirrhosis.
However, several studies have shown that routine diagnostic
tests, such as platelet count, bleeding time, PFA-100, thrombo-
elastography are not clinically useful to stratify bleeding risk in
patients with cirrhosis. Moreover, treatments used to increase
platelet count or to modulate platelet function could potentially
do harm. Consequently the optimal management of bleeding
complications is still a matter of discussion.
Moreover, in the last two decades there has been an increased
recognition that not only bleeding but also thrombosis compli-
cates the clinical course of cirrhosis. Thus, we performed a litera-
ture search looking at publications studying both qualitative and
quantitative aspects of platelet function to verify which primary
haemostasis defects occur in cirrhosis. In addition, we evaluated
the contribution of qualitative and quantitative aspects of platelet
function to the clinical outcome in cirrhosis and their therapeutic
management according to the data available in the literature.
From the detailed analysis of the literature, it appears clear
that primary haemostasis may not be defective in cirrhosis, and
a low platelet count should not necessarily be considered as an
automatic index of an increased risk of bleeding. Conversely, cau-
tion should be observed in patients with severe thrombocytope-
nia where its correction is advised if bleeding occurs and before
invasive diagnostic and therapeutic procedures.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Complex haemostatic changes coexist in liver cirrhosis (LC) [1–4].
These changes include defects in primary haemostasis, abnormal-
ities of the clotting system due to impaired synthesis ofJournal of Hepatology 20
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abnormalities in laboratory tests reﬂecting changes in primary
haemostasis, including bleeding time (BT), platelet aggregation
tests, and platelet count. Laboratory tests of platelet function con-
sistently show that primary haemostasis is impaired in cirrhosis
as a consequence of reduced platelet function and/or low platelet
count [5]. Such changes have been considered particularly rele-
vant in the bleeding complications that occur in cirrhosis, so that
the clinical effect of drugs that improve platelet function [6–9], or
number of platelets [10] has been investigated in cirrhosis.
However, in the last two decades, there has been an increased
recognition that not only bleeding but also thrombosis compli-
cates the clinical course of cirrhosis. Portal vein thrombosis is a
frequent ﬁnding in cirrhosis (without concomitant hepatocellular
carcinoma) occurring in about 10–20% of LC [11–14]. Moreover,
the occurrence of thrombosis in other vascular territories, such
as peripheral veins, is increasingly being reported. Patients with
cirrhosis are prone to deep vein thrombosis and embolic disease
[15–17], as evidenced by epidemiological data [18]. Thus, a
review of primary haemostasis within the newly accepted para-
digm of preserved haemostasis in cirrhosis, with normal throm-
bin formation [19], or increased thrombin generation [20], and
the coexistence of bleeding and thrombotic complications in
cirrhosis [3], and its possible role in these abnormalities is
pertinent.
We performed a literature search looking at publications
studying both qualitative and quantitative aspects of platelet
function to verify which primary hemostasis defects occur in cir-
rhosis, and if so, how they contribute to clinical outcome.Primary haemostasis: physiology
Haemostasis is the process that maintains the integrity of the cir-
culatory system after vascular damage. Platelets are recruited to
the site of injury where they become a major component of the
developing thrombus. When pathologic processes overwhelm
the regulatory mechanisms of haemostasis either thrombosis or
bleeding can occur.
The endothelium is crucial in providing a defense against
thrombus formation: it contains thromboregulators able to
inhibit platelet activation such as nitric oxide, [21,22], prostacy-
clin, [23] and the endothelial ectoadenosine diphosphatase11 vol. 55 j 1415–1427
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Fig. 1. Primary haemostasis: physiology. Platelets, anucleated cells derived from megakaryocytes, at the side of vessel wall injury, adhere to exposed collagen or vWf.
Adhesion and activation is initiated by two distinct pathways acting in parallel or separately: (A) exposure of sub-endothelial collagen initiates platelet activation via Gp VI
binding to the collagen and Gp Ib-V-IX exposure of collagen triggers the adhesion and activation of platelets; (B) TF initiates the generation of thrombin. (C) After adhesion
to endothelium, in the activation phase, thrombin derived by coagulation cascade and platelets-derived mediators, such as ADP, TXA2 and isoprostanes, activate several
pathways resulting in glycoprotein IIb/IIIa activation and in turn platelet aggregation. AA, arachidonic acid; ADP, adenosine diphosphate; COX1, cyclo-oxygenase 1; GP,
glycoprotein; NADPH-Ox, NADPH oxidase; TF, tissue factor; TP, thromboxane receptor; TXA2, thromboxane A2; vWf, Von Willebrand factor.
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(ecto-ADPase) pathway [24]. When the endothelium is disrupted,
collagen triggers the adhesion and activation of platelets,
whereas tissue factor (TF) initiates the generation of thrombin,
which not only converts ﬁbrinogen to ﬁbrin but also activates
platelets. The initial platelet adhesion is followed by activation
which is characterized by these phases: (i) platelet granule
release reaction that facilitates further platelet activation and
platelet recruitment, (ii) cytoskeletal rearrangements (necessary
for shape change including spreading, pseudopodia formation,
and clot retraction), (iii) mobilization of arachidonic acid to
amplify intracellular signaling, (iv) glycoprotein (Gp) IIb/IIIa
expression on the surface of the platelet for aggregation mediated
by the receptors and ﬁbrinogen and (v) exposure of procoagulant
phospholipids to facilitate coagulation.
Recent studies of thrombus formation in genetically altered
mice [25,26] show two distinct pathways acting in parallel or
separately, for platelet activation. In the ﬁrst pathway, exposure
of sub-endothelial collagen initiates platelet activation via Gp
VI binding to the collagen and Gp Ib-V-IX binding to collagen-
bound von Willebrand factor (vWf). In the second one, TF initi-
ates platelet activation independently of vWf [27] and GpVI
[26]. It forms a complex with factor VIIa, initiating a proteolytic
cascade that generates thrombin. Thrombin thereby activates
platelets [28] through PAR4 receptors causing them to release
adenosine diphosphate (ADP), serotonin, and thromboxane (Tx)
A2. The consequences of platelet activation triggered by these
pathways are identical [25,26].
Platelet activation and aggregation
Thrombus formation is a dynamic process in which some plate-
lets adhere to and others separate from the developing thrombus
[27]. Activation of platelets bound to the injured vessel wall
causes a conformational transition in GpIIb/IIIa that increases
its afﬁnity for ﬁbrinogen and vWf [29]. At low shear rates ﬁbrin-
ogen is the predominant ligand, whereas vWf plays an important
role at higher shear rates [30,31]. Neither vWf nor ﬁbrinogen is
required for platelet accumulation [32]. Propagation of platelet
activation depends upon interaction of several agonists with
receptors expressed on platelets themselves. Three outside-in
signals of particular relevance are mediated by ADP, thrombin
and TxA2 [33] and responsible for platelet activation and
aggregation.
Platelets express at least two ADP receptors, P2Y1 and P2Y12.
The activation of P2Y12 inhibits adenylate cyclase causing a
decrease in the cyclic AMP (cAMP) level and the activation of
P2Y1 causes an increase in the intracellular Ca2+ level. The
P2Y12 receptor is the major receptor able to amplify and sustain
platelet activation in response to ADP, by facilitating the release
of intracellular calcium stores by decreasing cAMP levels in the
platelet.
Platelets produce two eicosanoids, namely TXA2 and isopros-
tanes with pro-aggregating properties. TXA2 derives from enzy-
matic oxidation of arachidonic acid by COX1 while isoprostanes
derive from non-enzymatic oxidation of arachidonic acid by
reactive oxidant species (ROS)-generated nicotinamide adenine
dinucleotide phosphate-oxidase (NADPH) oxidase [34]. While
TXA2 serves for the initial phase of platelet activation, isopros-
tanes are implicated in the propagation of platelet aggregation
along with ROS and ADP release from activated platelets
(Fig. 1).Journal of Hepatology 2011Global tests for primary haemostasis and bleeding
Bleeding time
The skin bleeding time (BT) (Table 1) is an easy and frequently
used global test for primary haemostasis [35,36]. Because the
BT is prolonged in congenital and acquired platelet defects, it
has been common reasoning for years that this test could provide
a screening for hemorrhagic tendencies in other platelet
disorders.
The Simplate template device is the technique most com-
monly used to measure BT with an upper limit of normal being
between 9 and 10 minutes [36]. However, this test may be sensi-
tive to a variety of variables that may produce false-positive and
false-negative results. Thus, it is not only inﬂuenced by the plate-
let count and function, but may also be affected by the packed
cell volume, blood urea concentration, platelet volume, and the
nature of skin connective tissue. In haematological (bone mar-
row) causes of thrombocytopenia (TCP) there is a direct correla-
tion between BT and platelet count <100  109/L [37].
On this basis, BT has been used to measure primary haemosta-
sis in cirrhosis [38,39]. However, in 100 patients with cirrhosis,
Blake et al. [38] showed that only 42% had BT prolongation, which
could be explained only in part by a concomitant TCP. In fact,
there was only a weak correlation between BT and platelet count.
A prolonged BT in LC patients with platelet counts greater than
100  109/L, a level typically regarded within ‘‘safe limits’’ for
invasive procedures, was observed in some patients, and con-
versely there was a normal BT in some patients with platelet
count <100  109/L. Liver failure itself is associated with prolon-
gation of BT. A prospective study conducted in seventy LC
patients demonstrated a progressive prolongation of BT from
Child-Pugh class A to class C patients [40]. Nevertheless, the clin-
ical value of BT prolongation as risk factor for bleeding in liver
cirrhosis remains uncertain. Boberg et al. [41] reported that a pro-
longed BT was associated with a 5-fold increase risk of hemoglo-
bin reduction after liver biopsy. Two retrospective studies [39,42]
showed a signiﬁcant association between BT and a previous his-
tory of gastrointestinal-haemorrhage, but a prospective study
failed to conﬁrm this association [43]. Thus, in patients with cir-
rhosis without previous bleeding, only variceal size and severe
liver failure, but not BT, signiﬁcantly predicted bleeding events
during one-year follow-up [43]. It is therefore possible that the
prolongation of BT will have a different impact on provoked (liver
biopsy) or spontaneous (gastrointestinal bleeding) bleeding but
literature data are not sufﬁcient to support such hypothesis.
The poor association of BT as risk factor for bleeding in cirrho-
sis is supported by interventional studies with drugs that increase
platelet vascular adherence and activation [6–9]. Thus, treatment
with desmopressin (DDAVP), a synthetic peptide homologous to
human vasopressin that is usually employed in congenital bleed-
ing disorders such as von Willebrand’s disease, was able to
shorten the prolonged BT in patients with cirrhosis [6,7]. This is
probably due to the increase in von Willebrand factor (vWF)
and FVIII seen after administration of DDAVPwhich possibly com-
pensates for the thrombocytopenia. However, de Franchis et al. [8]
showed that in LC patients with active variceal hemorrhage, on
treatment with terlipressin, recurrence of bleeding occurredmore
frequently in patients who received desmopressin compared to
those who did not (54% vs. 27%, respectively). In addition, desmo-
pressin did not reduce the transfusion requirement in patientsvol. 55 j 1415–1427 1417
Table 1. Tests for assessing primary hemostasis.
Platelet tests Description Pro Con
Haemostasis global tests
In vivo bleeding time 
assessment
The time it takes for a standardized skin wound to stop 
bleeding
The bleeding time measures the ability of platelets to arrest 
bleeding and, therefore, is a measure of both platelet number 
and function
Physiological (platelet-
vessel interaction)
Cheap 
No specialised labora-
tory required
blood sampling 
Not influenced by
Poorly reproducible
Invasive
Insensitive
Time consuming
No correlation with 
bleeding tendency
Thromboelastography Blood clots in a backward and forward rotating sample cup 
around a suspended pin. Because of clot formation, the cup’s 
motions become limited. These movements are mapped and 
different variables (depending on coagulation, fibrinolysis and
platelet function) can be calculated
Global haemostasis
Automated
Point of care test
Rapid and Simple to 
perform
Commonly used for 
helping define thresh-
olds of transfusion 
Measures Clot
properties only
Not sensitive to plate-
let function 
PFA-100 The test attempts to mimic in vivo shear-dependent platelet 
function.  It measures the closure time (CT), by platelets, of an 
aperture in a membrane coated with either collagen/ADP or 
collagen/epinephrine
Simple to perform
Rapid 
Small volumes
Citrated blood up to 
4 h
Sensitive to many
variables (haema-
tocrit, drug, dietary 
effects) 
Can give false nega-
tive results
Platelet Function Assessment
$JJUHJRPHWU\ 7HVWVWKHin vitroDELOLW\RISODWHOHWVWRVWLFNWRRQHDQRWKHULH
SODWHOHWDJJUHJDWLRQLQUHVSRQVHWRVWLPXODWLRQE\DSDQHORI
H[RJHQRXVDJRQLVWV>FROODJHQWKURPELQDGHQRVLQHGLSKRV
SKDWH$'3HWF@
3ODWHOHW5LFK3ODVPD3530HWKRGRSWLFDOOLJKWWXUELGLW\LV
DPHDVXUHRIDJJUHJDWLRQ
:KROH%ORRG0HWKRGHOHFWULFDOLPSHGDQFHPHDVXUHPHQW
9DOXDEOHIRULGHQWLI\
LQJDQGGLDJQRVLQJ
SODWHOHWIXQFWLRQ
GHIHFWVZKLFKDUH
LQKHULWHGRUVHFRQGDU\
WRGUXJV
6SHFLDOLVHGODERUD
WRU\UHTXLUHG
7HVWSODWHOHWVXQGHU
XQSK\VLRORJLFDO
FRQGLWLRQV/RZ
VKHDUFRQGLWLRQVDQG
LQIUHHVROXWLRQZLWKLQ
353
3HUIRUPHGZLWKLQK
RIEORRGVDPSOLQJ
)ORZF\WRPHWULFTXDQ
PROHFXOHH[SUHVVLRQ
WLILFDWLRQRIPHPEUDQH
FHOOVRUWLQJ)$&6
>IOXRUHVFHQWDFWLYDWHG
DQDO\VLV@
(YDOXDWHVWKHSUHVHQFHRIVWLPXODWLRQGHSHQGHQWDQWLJHQV>HJ
&'33VHOHFWLQ@RUSODWHOHWOHXFRF\WHFRPSOH[HV0HDVXUH
RISODWHOHWDFWLYDWLRQ
:KROHEORRGWHVW
)OH[LEOH
:LGHYDULHW\RIWHVWV
DYDLODEOH
2QO\VPDOOTXDQWLWLHV
RIEORRGDUHUHTXLUHG
0D\KHOSSUHGLFW
SDWLHQWVDWULVNRI
WKURPERVLV
([SHQVLYHLQVWUXPHQW
DQGVSHFLDOLVHGODER
UDWRU\UHTXLUHG
1HYHUHYDOXDWHGIRU
DVVHVVLQJEOHHGLQJ
ULVN
0HDVXUHPHQWRI6ROX
EOHDFWLYDWLRQPDUNHUV
7RPHDVXUHSODWHOHWUHOHDVHSURGXFWVZLWKLQSODWHOHWSRRU
SODVPDE\UDGLRLPPXQRDVVD\V5,$VDQGRUHQ]\PHOLQNHG
LPPXQRVRUEHQWDVVD\V(/,6$V
- 6ROXEOH3VHOHFWLQ
- 3)DQG˟7*
- 6ROXEOH&'/
6LPSOHV\VWHPLF
PHDVXUHRISODWHOHW
DFWLYDWLRQPD\KHOS
SUHGLFWSDWLHQWVDWULVN
RIWKURPERVLV
3URQHWRDUWHIDFW
&DUHIXOKDQGOLQJ
DQGEORRGSURFHVVLQJ
&DQQRWSUHGLFWULVNRI
EOHHGLQJ
3ODWHOHW$GKHVLRQWHVW
XQGHUIORZFRQGLWLRQV
$VVD\VWKDWWU\WRVLPXODWHWKH
XQGHUIORZFRQGLWLRQVWRVWXG\VKHDULQGXFHGSODWHOHWDFWLYD
in vivoSODWHOHWIXQFWLRQin vitro
WLRQ
6LPXODWHSK\VLRORJL
FDOFRQGLWLRQ
6PDOOYROXPHVRI
FLWUDWHGEORRGXSWR
KIURPVDPSOLQJ
([SHQVLYHLQVWUX
PHQWDQGVSHFLDOLVHG
ODERUDWRU\UHTXLUHG
6HQVLWLYHWRPDQ\
HQFHSODWHOHWIXQFWLRQ
YDULDEOHVWKDWLQIOX
SODWHOHWFRXQW
KDHPDWRFULWGUXJ
DQGGLHW
Molecular mechanism 
detection of platelet 
function
The concentrations of second messengers [e.g. calcium, 
cyclic adenosine monophosphate (cAMP)], and the release of 
platelet granules containing proaggregatory molecules [seroto-
nin, adenosine triphosphate (ATP), PF4, bTG]
Molecular insight Expensive instru-
ment and specialised 
laboratory required
Reviewundergoing hepatectomy [9]. The limited effect of desmopressin
in increasing the size of the vWF complexes [44], also suggests a
reduced or ineffective action of this drug in cirrhosis.1418 Journal of Hepatology 2011As platelet activation is not diminished but can be increased
in cirrhosis, it is possible that BT prolongation in these patients
results more from changes in vasoreactivity and/or arterialvol. 55 j 1415–1427
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dysfunction which are well documented in cirrhosis [45], than
from platelet number or function. Enhanced platelet activation
could also explain the normal BT found in some patients with cir-
rhosis despite low platelet counts [7,38].
Platelet function assay (PFA)-100
The PFA-100 (Table 1) test attempts to mimic in vivo shear-
dependent platelet function. It measures the closure time (CT),
by platelets, of an aperture in a membrane coated with either col-
lagen/ADP or collagen/epinephrine. While it may substitute for
skin bleeding-time testing in the assessment of suspected von
Willebrand’s disease and qualitative platelet disorders [46], it
appears to be of limited value in other settings compared to
healthy controls. Prolonged CT occurs in patients with end stage
liver disease [47] as well as in stable cirrhotic patients [48,49].
Nevertheless, the prognostic value of abnormal PFA-100 in pre-
dicting bleeding complications in LC patients has never been
investigated [50].
Thromboelastography (TEG)
Recently, other global in vitro laboratory tests such as Thrombe-
lastography (TEG) have been developed to explore both platelet
and clotting function. TEG gives information on clotting factor
activity, platelet function, and ﬁbrinolysis. TEG abnormalities
indicating hypercoagulability have been reported in LC [51,52].Alcohol, virus
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Fig. 2. Mechanisms of thrombocytopenia in liver cirrhosis. Thrombocytopenia in liver
platelet production and (2) platelet survival. Factors that decrease platelet production: (a)
and (b) the inadequate thrombocytopoiesis for abnormal thrombopoietin production o
splanchnic sequestration secondary to portal hypertension (b) autoantibodies directed ag
the splenic and hepatic reticulo-endothelial systems (c) increased platelet consumption
Journal of Hepatology 2011Recently, PlateletMapping using TEG technology has been sug-
gested as a potentially useful and novel approach to evaluate
platelet function in patients with cirrhosis [53,54] (Table 1).
These tests require further evaluation to verify their utility in var-
ious clinical situations.Thrombocytopenia and cirrhosis
Thrombocytopenia is deﬁned as any decrease in platelet count
below the lower normal limit, which is usually around 140 x
109/L. TCP is a common ﬁnding in cirrhosis and reported in as
many as 76% of patients [55].
However, thrombocytopenia has not been associated with an
increased risk of bleeding from esophageal varices or other sites,
although it is correlated with blood loss during surgery [56].
Moderate TCP (50–75  109/L) is observed in approximately
13% of patients with cirrhosis. Severe TCP, deﬁned as platelet
count less than 50  109/L occurs in only 1% of patients [57]. This
threshold is often used as a cut-off when managing patients with
cirrhosis, as a contraindication for elective invasive procedures
for example liver biopsy, paracentesis, thoracentesis, because of
an assumed increased risk of bleeding [58–61]. Often platelet
transfusions are used prophylactically to cover similar
procedures.
Thus, as in any critically ill patient [62], severe TCP could
impact the routine care of liver cirrhosis patients [63], potentiallyAntiplatelet 
antibodies
Ab
Secondary to 
platelet activation
Decreased 
platelet survival
Hypersplenism and
portal hypertension
ytopenia
cirrhosis is traditionally believed to be the result from an imbalance between (1)
direct bone marrow suppression caused by the underlying etiology o liver disease
r activity. Factors decreasing platelet survival include: (a) enhanced splenic and
ainst platelet surface antigens that produce an augmented removal of platelets by
as a result of platelet activation.
vol. 55 j 1415–1427 1419
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postponing or interfering with diagnostic and therapeutic proce-
dures including liver biopsy, antiviral therapy, and medically
indicated or elective surgery.
Accordingly, Tripodi et al. [64] documented that thrombocyto-
penia limits thrombin generation in LC patients so potentially
predisposing to bleeding tendency. Thus, platelet transfusion
might be useful only in patients with low platelet counts during
acute bleeding or before undergoing surgery or liver biopsy.Mechanisms of thrombocytopenia
The pathogenesis of TCP in cirrhosis is still not fully understood.
Multiple factors have been proposed for the pathogenesis of TCP
in advanced liver cirrhosis. Traditionally TCP is believed to result
from an imbalance between platelet production and platelet sur-
vival (Fig. 2).Decreased platelet production
Bone marrow suppression
Suppression of platelet production in the bone marrow can be
caused by the underlying etiology of the liver disease [65–67].
Thus, in chronically infected hepatitis C (HCV) patients, either
HCV itself or interferon treatments [68] seem to be responsible
for bone marrow suppression and eventually TCP [69]. Alcohol
is another factor causing TCP via direct inhibition of megakaryo-
cyte maturation and ultimately platelet formation [70,71]. Cir-
rhotic patients might also have dietary deﬁciencies like in the
case of vitamin B12, folic acid and iron that could also contribute
towards thrombocytopenia.
Altered thrombopoietin metabolism
Liver cells produce thrombopoietin (TPO), an important cytokine
affecting megakaryocytes ploid amount, growth, and size [72].
Low TPO-mRNA expression was detected in the liver of patients
with advanced liver disease and could be responsible for a deﬁ-
cient hepatic thrombopoietin production [73,74]. Accordingly,
patients with LC and TCP revealed signiﬁcantly lower reticulated
platelet levels than LC patients without TCP [72,75]. Moreover,
after orthotopic liver transplantation an increase of TPO was
observed [76,77].
However, the clinical impact of these data is confused by the
divergent results on serum TPO levels, including normal,
decreased or increased in LC [72,74–83]. This issue may be con-
sequent to an inadequate standardization of TPO laboratory
assays that should be solved in the future [84].Decreased platelet survival
Hypersplenism and portal hypertension
The original theory by Aster et al. [85] suggested that in LC, TCP
could exclusively be explained by an increased pooling of plate-
lets in the enlarged spleen because of portal hypertension. Thus,
kinetic radiolabelled platelet studies showed shorter platelet1420 Journal of Hepatology 2011survival time [86]. Additionally, partial splenic embolization
demonstrated an increase in platelet count suggesting a contribu-
tion of splenic sequestration in TCP [87,88]. Despite these ﬁnd-
ings, a direct correlation between portal pressure or spleen size
and platelet count was never ﬁrmly demonstrated.
Gastroesophageal varices (GEV), a direct consequence of por-
tal hypertension, appear to be associated with a wide range of
TCP (ranging from 68 to 160  109/L) as showed by several
cross-sectional studies [89–93] performed in decompensated
and compensated LC patients [94,95]. Thus, Giannini et al. [55]
proposed platelet count/spleen diameter ratio as a non-invasive
predictor of GEV; the diagnostic accuracy of this ratio for GEV
was 86% with a negative predictive value of 87% [96]. However,
normalization of portal pressure with transjugular portosystemic
shunts (TIPS) could not consistently demonstrate a beneﬁt in
terms of platelet count [97,98].
Platelet-associated antibodies
Increased levels of immunoglobulin G (IgG) bound to platelets,
suggest the presence of autoantibodies reactive with platelets
in patients with chronic liver disease [79,99]. Autoantibodies
directed against platelet surface antigens can enhance removal
of platelets by the splenic and hepatic reticulo-endothelial sys-
tems. This is clearly the case in certain patients with hepatitis C
[100]. Nevertheless, the role of these antiplatelet antibodies in
TCP in other causes of cirrhosis is still unclear because of their
nonspeciﬁc binding to platelet surface [100,101].
Platelet consumption
Platelet activation, with ensuing platelet consumption, could be
implicated in TCP of LC (see paragraph: Thrombocytopathy).
Low-grade disseminated intravascular coagulation may play a
role as suggested by the concomitant increase of prothrombin
fragment 1+2 (F1+2) and D-dimer in advanced LC [4]. Endotoxe-
mia may be implicated as LC patients treated with non-absorb-
able antibiotics showed a signiﬁcant and simultaneous
reduction of endotoxemia, F1+2, and D-dimer plasma levels [4].
Furthermore, endotoxemia per se could reduce peripheral blood
counts either directly or indirectly though the release of cyto-
kines [102,103]. Thus, Kalambokis et al. showed that intestinal
decontamination lowered endotoxaemia and raised peripheral
blood counts by inhibiting cytokines and enhancing the produc-
tion of nitric oxide (NO), a potent vasodilator and anti-aggregat-
ing molecule [104].Co-existing conditions and bleeding risk in LC patients
Anemia may complicate the clinical course of cirrhosis and could
theoretically predispose to bleeding by impairing platelet func-
tion. Thus, red cells activate platelet COX1 [105], inactivate NO
[106] and greatly contribute to vessel repair by favoring platelet
attachment to damaged vasculature [107]. However, the impact
of anemia on bleeding complication of cirrhotic patients needs
to be further investigated along with exploring the cost/beneﬁt
of red cell transfusion in case of cirrhosis with associated anemia
[107]. It has been shown that a restrictive transfusion approach
(target hemoglobin level: 7.0 and 9.0 g/dl) was as effective asvol. 55 j 1415–1427
Table 2. The advantages and disadvantages of strategies available to prevent bleeding in patients with liver cirrhosis: focus on platelet count and function.
Strategies Pro Con
Platelet  transfusion Improves primary haemostasis 
Restore thrombin generation to normal (if platelet 
count rises to more than 50,000 per microliter)
Transfusion-related side effects
Negative impact on liver transplantation outcome
Fluid overload and Exacerbation of portal hypertension
Red cell transfusion Improves  platelet function Transfusion-related side effects
Negative impact on liver transplantation outcome
Fluid overload and Exacerbation of portal hypertension
1-desamino-8-D-
arginine vasopressin 
(DDAVP)
Laboratory improvement of primary haemostasis
Well tolerated
Simple to administrate
Thrombopoietin
Receptor agonists
Increases endogenous platelet count
No transfusion-related side effects Safety issues (risk of thrombosis, rebounded thrombo-
cytopenia)
JOURNAL OF HEPATOLOGYand possibly superior to a more liberal transfusion policy
[108], accompanied by reduction of transfusion-related side
effects.
A restrictive transfusion policy should also be adopted during
liver transplantation procedures. Indeed, it has been shown that
transfusion of red cell concentrates, as well as the amount of
transfused blood product, could be associated with a reduced
graft and patient survival [109].
Patients with cirrhosis have increased risk to develop sepsis
and sepsis-related complications [110,111]. Endotoxemia-related
sepsis could promote platelet aggregation, microvascular
obstruction, and tissue injury [112] and eventually platelet
exhaustion with subsequent enhanced risk of bleeding [113]. Of
note, prophylactic antibiotic therapy can reduce the early re-
bleeding after a ﬁrst bleeding episode and permits a better con-
trol of active bleeding [114].Treatment of thrombocytopenia in liver cirrhosis
Thrombocytopenia may have a negative impact on clinical man-
agement of patients. Therapeutic platelet transfusions are
unequivocally indicated for patients with active bleeding associ-
ated with thrombocytopenia [115]. There is consensus that the
platelet count should not be allowed to fall below 50  109/L in
patients with acute bleeding.
According to the guidelines for the general use of platelet
transfusions [115], a threshold of 10  109/L is as safe as higher
levels for patients without additional risk factors such as sepsis,
concurrent use of antibiotics or other abnormalities of
haemostasis.
However, in patients with advanced liver disease there is
a lack of consensus regarding the degree of thrombocytope-
nia that may be associated with an increased risk of bleed-
ing [116,117]. Thus, speciﬁc guidelines in LC are lacking to
indicate the platelet cut-off below which procedures (as
well as liver transplantation) should be delayed and/or
platelet transfusions or platelet-stimulating agents should
be administrated.
Several therapeutic options (Table 2) are currently available to
raise platelet count to a safe level for invasive procedures or in
case of active bleeding.Journal of Hepatology 2011Therapeutic options
Platelet transfusion (PT)
Platelet transfusion (PT) is the standard-of-care in general to
temporarily increase platelet counts prior to invasive procedures
[115]. Current recommendations for PT [115] concerning liver
biopsy, lumbar puncture, epidural anaesthesia, or similar proce-
dures in patients with chronic and stable thrombocytopenia
suggest that the platelet count should be raised to at least
50  109/L.
Recently, the American Association for the Study of Liver Dis-
ease guidelines [118] recommend that platelet transfusion before
liver biopsy, transcutaneously or transvenously, should be con-
sidered when levels of platelet count are less than 50–60  109/
L (Class 1, Level C i.e. without evidence from randomized studies).
Thus, in LC randomized controlled studies, assessing efﬁcacy and
safety of restrictive PT strategies in thrombocytopenic patients
during invasive procedures such as liver biopsy, are needed
[119]. Moreover, PT seems to be inappropriate for long-term
management partially due to potential allo-immunization and
also because shortened allogeneic platelet survival due to seques-
tration in enlarged spleens. In addition, in liver transplant
patients, platelet transfusions have been associated with
increased post-operative mortality, as a result of an increased risk
of acute lung injury [120]. Additionally, there are no data to sup-
port beneﬁt of PT strategies in subjects with TCP and variceal
bleeding [121].
Splenectomy or partial splenectomy
Splenectomy or partial splenectomy by embolization can par-
tially reverse TCP in patients with liver disease [122]. However,
these procedures are not routinely recommended for their immu-
nological consequence (impaired immunity and bacterial vacci-
nation) and the non-negligible associated mortality and
morbidity [123].
TPO targeting agents
Recently, the role of TPO targeting agents (Table 3) has also
been tested. Currently, only two TPO mimetics, Romiplostinvol. 55 j 1415–1427 1421
Table 3. Agents targeting thrombopoietin (TPO) pathway.
Agents Mechanism of action Administration 
route
Pro Con
First-generation
thrombopoietins
(Recombinant human 
TPO-rhTPO- and 
pegylated recombinant 
human megakaryocyte 
growth and develop-
ment factor
-PEG-rHuMGDF)
TPO receptor agonist Subcutaneous Increase megakaryopoiesis 
and thrombopoiesis
Immunogenic issues (de-
velopment of antibodies 
against PEG-rHuMGDF, 
which cross-reacted with 
and neutralized endog-
enous TPO, producing 
thrombocytopenia)
platelet activation
(Risk of thrombosis)
Use abandoned in 1998
Second-generation
thrombopoietins
(TPO peptide mimetic 
-romiplostim- and
TPO nonpeptide mi-
metic -eltrombopag-)
TPO receptor agonist Subcutaneous: peptide 
mimetic
Oral: non peptide 
mimetic
Dose-dependent increase 
in platelet counts
Management of hepatitis C 
virus-related thrombocytopenia 
Well tolerated,
(Mild headache-most common 
side effect)
Non immunogenic TPO
Potential long-term com-
plications
(risk of thrombosis,  
rebound worsening of 
thrombocytopenia upon 
discontinuation)
Cytokines with potent 
thrombopoietic activity
(Recombinant human
interleukin-11 -rhIL-11-)
IL-11 mimetic Subcutaneous Increase in platelet counts Toxicity
High Cost
Reviewand Eltrombopag, have been approved for the treatment of
idiopathic thrombocytopenic purpura [124]. They seem to
be potentially useful before invasive procedure in TCP
patients. Nevertheless, the higher incidence of portal axis
thrombosis in patients with advanced liver disease, observed
in a recent trial, prompted the FDA to advise against use
of TPO mimetics in LC patients (ClinicalTrials.gov Identiﬁer:
NCT00678587).Thrombocytopathy in liver cirrhosis
The belief that cirrhosis is associated with impaired platelet acti-
vation has been based on the existence of changes of laboratory
tests exploring platelet aggregation. Thus, decreased agonist-
induced platelet aggregation (PA) by common agonists such as
thrombin, collagen, ADP, epinephrine, and arachidonic acid has
been detected in LC [125–128]. Intra- and extra-platelet mecha-
nisms including multiple defects in signal transduction or storage
pool defect and membrane-related defects caused by enhanced
high-density lipoprotein (HDL) apolipoprotein E content were
all considered to account for platelet dysfunction [125, 128]
(Table 4).
However, more recent data have questioned this hypothesis.
For instance, the urinary excretion of 11-deydro-thromboxane1422 Journal of Hepatology 2011(Tx) B2, a stable metabolite of TxA2, was increased in cirrhosis
suggesting that platelets could be activated [129]. Although
this interpretation cannot be fully supported by the data of
11-deydro-TxB2 urinary excretion as it only partly reﬂects
the activation of platelet COX1 [130], other studies also seem
to support the existence of enhanced platelet activation in cir-
rhosis. Soluble P-selectin (sPs), which is an in vivo marker of
platelet activation is consistently elevated in plasma particu-
larly in cases of severe liver disease and correlated with
markers of hepatic protein synthesis and low platelet counts
[131–133].
More recent ﬂow cytometry analysis of platelet activation, as
well as platelet-monocyte aggregates, is consistent with hyper-
activation of platelets in cirrhosis [134,135].
The discrepancy between the early studies of platelet aggrega-
tion suggesting platelet hypo-aggregability secondary to impair-
ment of platelet activation, and more recent studies showing
platelet over-secretion of P-selectin, suggesting increased platelet
COX1 activation, is not easy to explain. One issue is that aggrega-
tion tests in cirrhosis are intrinsically difﬁcult because the
reduced platelet count makes them difﬁcult to interpret since
these tests are dependent on platelet count.
The biological plausibility of platelet activation in cirrhosis
does not have a clear-cut mechanism either. Thrombin is the
key player in the clotting cascade and through platelet receptorsvol. 55 j 1415–1427
Table 4. Platelet function tests in patients with liver cirrhosis. (See below-mentioned references for further information.)
[Reference] Subjects (n) Platelet function test Results 
Ingerberg S et al., 1985 [144] 20 LC PA Reduced
et al., 1988 [125] 24 LC PA Reduced
Thromboxane Metabolites Increased
Desai K et al., 1989 [128] 30 LC PA Reduced
et al., 1992 [126] 31 LC PA Reduced
BTG/PF4 Increased
et al., 1993 [127] 12 LC PA Reduced
Mean platelet volume Increased
et al.,1996 [145] 9 LC PA Reduced
P-selectin stimulated expression Reduced
Thromboxane Metabolites Increased
Ferro D et al., 1996 [45] 32 LC vWF Antigen  and vWF ristocetin cofactor activity Increased
vWF Multimers No difference
Davì G et al., 1998 [129] 44 LC Thromboxane Metabolites Increased
Panasiuk A et al., 2001 [133] 27 LC sPs and BTG/PF4 Increased
Mean platelet volume Reduced
Ferroni P et al., 2001 [132] 39 CH HCV sPs and  vWF Antigen Increased
Pihusch R et al., 2002 [49] 25 CH
65 LC
Platelet Function Assay-100 Increased  (HCV 
and alcoholic LC);
Normal in PBC/PS
PMP  expression No difference 
vWF Antigen Increased
Ogasawara F et al., 2005 [134] 9 LC HCV
20 AFLD
sPs and PMP Increased
Lisman T et al., 2006 [138] 54 LC vWF Antigen and vWF ristocetin cofactor activity Increased
vWF Collagen Binding Capacity and vWF  Multimers Reduced
Vardareli E et al., 2007 [131] 40 LC sPs Increased if platelet 
count  <100x10-3/µl
Decreased in PTS 
with portal vein throm-
bosis
Sayed D et al., 2010 [135] 60 LC PMP Increased 
(in patients without 
bleeding  complica-
tions  and in patients 
with splenomegaly)
Ozhan H et al., 2010 [146] 70 NAFLD Mean platelet volume Increased
Ercin CN et al., 2010 [147] 50 NAFLD sPs No difference 
Kilciler G et al., 2010 [148] 60 NAFLD Mean platelet volume No difference
AFLD, alcoholic fatty liver disease; BTG, beta-thromboglobulin; CH, Chronic hepatitis; LC, Liver Cirrhosis; MPV, mean platelet volume, NAFLD, non alcoholic fatty liver
disease; PA, platelet aggregation; PBC, primary biliary cirrhosis; PF4, platelet factor 4; PMP, platelet micro-particles; PSC, primary sclerosing cholangitis; sPs, soluble P
selectin; vWF, von Willebrand Factor.
JOURNAL OF HEPATOLOGYPAR1 and 4 acts as a potent platelet activator. It is possible that
an enhanced in vivo formation of thrombin may account in part
for platelet activation. This is suggested by the correlation
between plasma levels of F1+2 and the urinary excretion of 11-Journal of Hepatology 2011dehydro-TxB2 [129]. The evidence that thrombin generation in
cirrhosis is normal or even increased [4,19,20] would ‘‘allow’’
for sufﬁcient thrombin despite the relatively low prothrombin
levels found in patients with cirrhosis.vol. 55 j 1415–1427 1423
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Changes in vWF may also play a role. vWF is a large, mul-
timeric protein with a crucial role in primary haemostasis,
since platelet–vWF interaction is one of the ﬁrst steps in plate-
let adhesion [136]. Accordingly, severe bleeding tendency has
been associated with vWF deﬁciency [137]. We have shown
that higher molecular weight multimers (HMWMs) of vWF
are present in cirrhosis. These HMWMs are more active in
binding platelets [44]. These data were conﬁrmed by Lisman
et al. [138] who demonstrated that in cirrhosis elevated vWF
plasma levels resulted in a substantially elevated platelet depo-
sition on collagen in a vWF-dependent, ﬂow-driven, platelet
adhesion assay. The increased adhesion induced by plasma
from patients with cirrhosis was observed with both normal
and patients’ platelets, and was independent of platelet count.
This indicates that the increase in vWF might in part compen-
sate for the quantitative platelet defects described in these
patients.Conclusions
Recent data from the literature indicate that stable patients with
LC may seldom have defects in primary haemostasis that predis-
poses them to bleeding. The prolongation of BT is not related
directly to platelet count unless a severe thrombocytopenia
deﬁned arbitrarily as 50 x 109/L or less is present.
The increased platelet activation by chronic inﬂammation
including increased endotoxemia, coupled with increased levels
of vWF may improve primary haemostasis. Similar compensatory
mechanisms need further elucidation.
To date the clinical impact of platelet hyperactivity in LC
patients has never been studied and needs to be clariﬁed.
An important aspect is whether platelet hyper-function has
some relationship with the thrombotic outcomes that may
complicate the clinical course of cirrhosis. Also, experimental
data demonstrate that platelet hyperactivity might be impli-
cated in the progression of liver disease [139,140], and ﬁbrosis
[141].
Accordingly, platelet activation is necessary to accumulate
virus-speciﬁc cytotoxic T lymphocytes and determine organ dam-
age in mouse models of acute viral hepatitis and antiplatelet
treatment seems capable of modulating it [140,142].
If a relationship with clinical outcomes is proven, then anti-
platelet or anticoagulant treatment may have a place in the man-
agement of compensated cirrhosis [143] but this hypothesis
needs to be carefully and cautiously explored.
In conclusion, our review indicates that platelet function or
primary haemostasis may not be defective in cirrhosis, and a
low platelet count should not necessarily be considered as an
automatic index of an increased risk of bleeding.
It is likely that treatments used to increase platelet count
in the chronic state could potentially harm the patient. Thus,
the recent report that LC patients with thrombocytopenia
experienced thrombosis of the portal venous system during
treatment with a thrombopoietin receptor agonist warrants
further evaluation. Conversely, caution should be observed
in patients with severe low platelet count (<50  109/L)
where correction of platelet count is advised if bleeding
occurs and before invasive diagnostic and therapeutic
procedures.1424 Journal of Hepatology 2011         Key Points
• Patients with cirrhosis can have abnormalities
in laboratory tests changes in primary
haemostasis.
• There is not universally accepted platelet function
assay in cirrhosis - this is needed in order to
establish evidence based clinical guidelines.
• Such changes have been considered particularly
relevant in the bleeding and thrombotic complica-
tions that occur in cirrhosis.
• Routine diagnostic tests, such as platelet count,
bleeding time, PFA-100, thrombelastography are
not clinically useful to stratify bleeding risk in LC
patients.
• Data from a randomized study suggests a
reduced or ineffective action of desmopressin
(DDVAP) administration in cirrhosis to prevent
variceal re-bleeding.
• The platelet count threshold for platelet
sion
an evidence base and needs further study.
prior to invasive procedures does not
transfu-
have
• The role of platelet transfusion for bleeding in 
cirrhosis does not have a universally accepted
protocol - this requires further study.Conﬂict of interest
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